| abstract |
The present invention provides new compounds of formula (I), wherein P3A, W, B, Q, Rl and R2 are defined as in formula (I); invention compounds are positive allosteric modulators of metabotropic receptors - subtype 5 ('mGluR5') which are useful for the treatment or prevention of central nervous system disorders such as for example: cognitive decline, both positive and negative symptoms in schizophrenia as well as other disorders in which the mGluR5 subtype of glutamate metabotropic receptor is involved. |